The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review Article Swipe
Rahil Sadat Shahtaheri
,
Shekoufeh Nikfar
,
Elahe Khorasani
,
Mansoureh Sabbagh-Bani-Azad
,
Zahra Goudarzi
,
Maziar Emamikhah
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.18502/cjn.v19i3.5427
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.18502/cjn.v19i3.5427
Background: Although widely used, first-line injectable medicines for the treatment of multiple sclerosis (MS) remain an issue of efficacy and adherence. Recently, new oral medications for MS have contributed to dramatic improvements in MS treatment. This study aims to evaluate the safety and efficacy of oral disease-modifying drugs (DMDs) used in relapsing-remitting MS (RRMS). Methods: A systematic review was conducted on related databases including PubMed, Scopus, Cochrane, and Web of Science up to April 2020. The screening of the studies and their quality assessment was carried out independently by the two authors. Results: Three studies fulfilled the predefined criteria of inclusion. One of them compared teriflonomide with subcutaneous interferon beta-1a (IFN β-1a), another compared oral fingolimod with intramuscular (IM) IFN β-1b, and the third article compared oral fingolimod with IM IFN β-1a. No eligible study was found for dimethyl fumarate (DMF). The results indicated that while the efficacy of fingolimod was more than IFN β (IM β-1a and β-1b), teriflunomide 7 mg had less efficacy than subcutaneous IFN β-1a. Regarding safety, the results indicated that the proportion of diabetic patients with adverse events (AEs) in the fingolimod group was higher than in the IFN β-1b group and the overall occurrence of AEs was similar between teriflunomide and IFN β-1a groups. Conclusion: There is evidence for the effectiveness of fingolimod in reducing annualized relapse rates (ARRs) and improving magnetic resonance imaging (MRI) findings, but the evidence does not support the effectiveness of teriflunomide and further studies are required to determine its efficacy. Also, fingolimod is associated with more side effects than IFN β-1b, but there is no evidence to suggest any difference in side effects between teriflunomide and IFN β-1a.
Related Topics
Concepts
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.18502/cjn.v19i3.5427
- OA Status
- diamond
- Cited By
- 1
- References
- 28
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3131449471
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3131449471Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.18502/cjn.v19i3.5427Digital Object Identifier
- Title
-
The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic reviewWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-02-17Full publication date if available
- Authors
-
Rahil Sadat Shahtaheri, Shekoufeh Nikfar, Elahe Khorasani, Mansoureh Sabbagh-Bani-Azad, Zahra Goudarzi, Maziar EmamikhahList of authors in order
- Landing page
-
https://doi.org/10.18502/cjn.v19i3.5427Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.18502/cjn.v19i3.5427Direct OA link when available
- Concepts
-
Teriflunomide, Fingolimod, Medicine, Multiple sclerosis, Dimethyl fumarate, Adverse effect, Glatiramer acetate, Relapsing remitting, Internal medicine, Oncology, Pharmacology, ImmunologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2024: 1Per-year citation counts (last 5 years)
- References (count)
-
28Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3131449471 |
|---|---|
| doi | https://doi.org/10.18502/cjn.v19i3.5427 |
| ids.doi | https://doi.org/10.18502/cjn.v19i3.5427 |
| ids.mag | 3131449471 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38011404 |
| ids.openalex | https://openalex.org/W3131449471 |
| fwci | 0.18453186 |
| type | review |
| title | The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review |
| biblio.issue | 3 |
| biblio.volume | 19 |
| biblio.last_page | 145 |
| biblio.first_page | 138 |
| topics[0].id | https://openalex.org/T10137 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9994000196456909 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2734 |
| topics[0].subfield.display_name | Pathology and Forensic Medicine |
| topics[0].display_name | Multiple Sclerosis Research Studies |
| topics[1].id | https://openalex.org/T10200 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9789999723434448 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2745 |
| topics[1].subfield.display_name | Rheumatology |
| topics[1].display_name | Rheumatoid Arthritis Research and Therapies |
| topics[2].id | https://openalex.org/T12477 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.9786999821662903 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Toxin Mechanisms and Immunotoxins |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777703276 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9880622625350952 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q3077133 |
| concepts[0].display_name | Teriflunomide |
| concepts[1].id | https://openalex.org/C2776036978 |
| concepts[1].level | 3 |
| concepts[1].score | 0.9880090951919556 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q425137 |
| concepts[1].display_name | Fingolimod |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.8703186511993408 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2780640218 |
| concepts[3].level | 2 |
| concepts[3].score | 0.7862657904624939 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q8277 |
| concepts[3].display_name | Multiple sclerosis |
| concepts[4].id | https://openalex.org/C2776819417 |
| concepts[4].level | 3 |
| concepts[4].score | 0.7331076860427856 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q418123 |
| concepts[4].display_name | Dimethyl fumarate |
| concepts[5].id | https://openalex.org/C197934379 |
| concepts[5].level | 2 |
| concepts[5].score | 0.6171169877052307 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[5].display_name | Adverse effect |
| concepts[6].id | https://openalex.org/C2778577042 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5919920802116394 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q418274 |
| concepts[6].display_name | Glatiramer acetate |
| concepts[7].id | https://openalex.org/C3020694758 |
| concepts[7].level | 3 |
| concepts[7].score | 0.47379419207572937 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q42417392 |
| concepts[7].display_name | Relapsing remitting |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.4601709246635437 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C143998085 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3453894257545471 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[9].display_name | Oncology |
| concepts[10].id | https://openalex.org/C98274493 |
| concepts[10].level | 1 |
| concepts[10].score | 0.3372167646884918 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[10].display_name | Pharmacology |
| concepts[11].id | https://openalex.org/C203014093 |
| concepts[11].level | 1 |
| concepts[11].score | 0.18553021550178528 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[11].display_name | Immunology |
| keywords[0].id | https://openalex.org/keywords/teriflunomide |
| keywords[0].score | 0.9880622625350952 |
| keywords[0].display_name | Teriflunomide |
| keywords[1].id | https://openalex.org/keywords/fingolimod |
| keywords[1].score | 0.9880090951919556 |
| keywords[1].display_name | Fingolimod |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.8703186511993408 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/multiple-sclerosis |
| keywords[3].score | 0.7862657904624939 |
| keywords[3].display_name | Multiple sclerosis |
| keywords[4].id | https://openalex.org/keywords/dimethyl-fumarate |
| keywords[4].score | 0.7331076860427856 |
| keywords[4].display_name | Dimethyl fumarate |
| keywords[5].id | https://openalex.org/keywords/adverse-effect |
| keywords[5].score | 0.6171169877052307 |
| keywords[5].display_name | Adverse effect |
| keywords[6].id | https://openalex.org/keywords/glatiramer-acetate |
| keywords[6].score | 0.5919920802116394 |
| keywords[6].display_name | Glatiramer acetate |
| keywords[7].id | https://openalex.org/keywords/relapsing-remitting |
| keywords[7].score | 0.47379419207572937 |
| keywords[7].display_name | Relapsing remitting |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.4601709246635437 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/oncology |
| keywords[9].score | 0.3453894257545471 |
| keywords[9].display_name | Oncology |
| keywords[10].id | https://openalex.org/keywords/pharmacology |
| keywords[10].score | 0.3372167646884918 |
| keywords[10].display_name | Pharmacology |
| keywords[11].id | https://openalex.org/keywords/immunology |
| keywords[11].score | 0.18553021550178528 |
| keywords[11].display_name | Immunology |
| language | en |
| locations[0].id | doi:10.18502/cjn.v19i3.5427 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210181665 |
| locations[0].source.issn | 2717-011X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2717-011X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Current Journal of Neurology |
| locations[0].source.host_organization | https://openalex.org/P4310319396 |
| locations[0].source.host_organization_name | Knowledge E |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319396 |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Current Journal of Neurology |
| locations[0].landing_page_url | https://doi.org/10.18502/cjn.v19i3.5427 |
| locations[1].id | pmid:38011404 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Current journal of neurology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38011404 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:8185589 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Curr J Neurol |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8185589 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5112779818 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Rahil Sadat Shahtaheri |
| authorships[0].countries | IR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[0].institutions[0].id | https://openalex.org/I70640408 |
| authorships[0].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[0].institutions[0].country_code | IR |
| authorships[0].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Rahil Sadat Shahtaheri |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[1].author.id | https://openalex.org/A5025053518 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5206-6197 |
| authorships[1].author.display_name | Shekoufeh Nikfar |
| authorships[1].countries | IR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[1].affiliations[0].raw_affiliation_string | Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I70640408 |
| authorships[1].affiliations[1].raw_affiliation_string | Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[1].institutions[0].id | https://openalex.org/I70640408 |
| authorships[1].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[1].institutions[0].country_code | IR |
| authorships[1].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Shekoufeh Nikfar |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran., Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[2].author.id | https://openalex.org/A5108126299 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6865-8250 |
| authorships[2].author.display_name | Elahe Khorasani |
| authorships[2].countries | IR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[2].institutions[0].id | https://openalex.org/I70640408 |
| authorships[2].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[2].institutions[0].country_code | IR |
| authorships[2].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Elahe Khorasani |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[3].author.id | https://openalex.org/A5018361832 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-1205-3057 |
| authorships[3].author.display_name | Mansoureh Sabbagh-Bani-Azad |
| authorships[3].countries | IR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[3].institutions[0].id | https://openalex.org/I70640408 |
| authorships[3].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[3].institutions[0].country_code | IR |
| authorships[3].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mansoureh Sabbagh-Baniazad |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[4].author.id | https://openalex.org/A5029278632 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7096-5276 |
| authorships[4].author.display_name | Zahra Goudarzi |
| authorships[4].countries | IR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[4].institutions[0].id | https://openalex.org/I70640408 |
| authorships[4].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[4].institutions[0].country_code | IR |
| authorships[4].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Zahra Goudarzi |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. |
| authorships[5].author.id | https://openalex.org/A5066778495 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-8375-5262 |
| authorships[5].author.display_name | Maziar Emamikhah |
| authorships[5].countries | IR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I161106909, https://openalex.org/I4210094544 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Neurology, Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. |
| authorships[5].institutions[0].id | https://openalex.org/I161106909 |
| authorships[5].institutions[0].ror | https://ror.org/03w04rv71 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I161106909 |
| authorships[5].institutions[0].country_code | IR |
| authorships[5].institutions[0].display_name | Iran University of Medical Sciences |
| authorships[5].institutions[1].id | https://openalex.org/I4210094544 |
| authorships[5].institutions[1].ror | https://ror.org/00kh76710 |
| authorships[5].institutions[1].type | healthcare |
| authorships[5].institutions[1].lineage | https://openalex.org/I4210094544 |
| authorships[5].institutions[1].country_code | IR |
| authorships[5].institutions[1].display_name | Rasool Akram Hospital |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Maziar Emamikhah |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Neurology, Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.18502/cjn.v19i3.5427 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10137 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9994000196456909 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2734 |
| primary_topic.subfield.display_name | Pathology and Forensic Medicine |
| primary_topic.display_name | Multiple Sclerosis Research Studies |
| related_works | https://openalex.org/W2564724011, https://openalex.org/W2404742406, https://openalex.org/W2052555685, https://openalex.org/W2545618539, https://openalex.org/W4389464789, https://openalex.org/W2904316116, https://openalex.org/W1666292467, https://openalex.org/W4256406638, https://openalex.org/W3017242812, https://openalex.org/W3155989692 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2024 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.18502/cjn.v19i3.5427 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210181665 |
| best_oa_location.source.issn | 2717-011X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2717-011X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Current Journal of Neurology |
| best_oa_location.source.host_organization | https://openalex.org/P4310319396 |
| best_oa_location.source.host_organization_name | Knowledge E |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319396 |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Current Journal of Neurology |
| best_oa_location.landing_page_url | https://doi.org/10.18502/cjn.v19i3.5427 |
| primary_location.id | doi:10.18502/cjn.v19i3.5427 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210181665 |
| primary_location.source.issn | 2717-011X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2717-011X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Current Journal of Neurology |
| primary_location.source.host_organization | https://openalex.org/P4310319396 |
| primary_location.source.host_organization_name | Knowledge E |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319396 |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Current Journal of Neurology |
| primary_location.landing_page_url | https://doi.org/10.18502/cjn.v19i3.5427 |
| publication_date | 2021-02-17 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W4210548604, https://openalex.org/W2038693293, https://openalex.org/W2093009907, https://openalex.org/W1815523758, https://openalex.org/W2043591841, https://openalex.org/W1986215651, https://openalex.org/W2096479500, https://openalex.org/W1967838438, https://openalex.org/W2093005278, https://openalex.org/W2139204856, https://openalex.org/W2151340435, https://openalex.org/W2010539762, https://openalex.org/W2133329597, https://openalex.org/W2124417387, https://openalex.org/W2118735809, https://openalex.org/W2105349127, https://openalex.org/W1966718542, https://openalex.org/W2051165446, https://openalex.org/W1970074129, https://openalex.org/W1979811627, https://openalex.org/W2104948944, https://openalex.org/W2172138286, https://openalex.org/W2766570001, https://openalex.org/W2129967156, https://openalex.org/W1480729244, https://openalex.org/W1986991730, https://openalex.org/W2009914030, https://openalex.org/W2179093540 |
| referenced_works_count | 28 |
| abstract_inverted_index.7 | 160 |
| abstract_inverted_index.A | 55 |
| abstract_inverted_index.IM | 129 |
| abstract_inverted_index.MS | 26, 33, 52 |
| abstract_inverted_index.No | 132 |
| abstract_inverted_index.an | 15 |
| abstract_inverted_index.by | 88 |
| abstract_inverted_index.in | 32, 50, 184, 191, 219, 271 |
| abstract_inverted_index.is | 212, 253, 264 |
| abstract_inverted_index.mg | 161 |
| abstract_inverted_index.no | 265 |
| abstract_inverted_index.of | 10, 17, 44, 69, 77, 99, 102, 148, 177, 200, 217, 240 |
| abstract_inverted_index.on | 60 |
| abstract_inverted_index.to | 29, 38, 72, 247, 267 |
| abstract_inverted_index.up | 71 |
| abstract_inverted_index.β | 154 |
| abstract_inverted_index.(IM | 155 |
| abstract_inverted_index.AEs | 201 |
| abstract_inverted_index.IFN | 119, 130, 153, 167, 193, 207, 260, 277 |
| abstract_inverted_index.One | 101 |
| abstract_inverted_index.The | 75, 141 |
| abstract_inverted_index.Web | 68 |
| abstract_inverted_index.and | 19, 42, 67, 80, 121, 157, 196, 206, 225, 242, 276 |
| abstract_inverted_index.any | 269 |
| abstract_inverted_index.are | 245 |
| abstract_inverted_index.but | 232, 262 |
| abstract_inverted_index.for | 7, 25, 137, 214 |
| abstract_inverted_index.had | 162 |
| abstract_inverted_index.its | 249 |
| abstract_inverted_index.new | 22 |
| abstract_inverted_index.not | 236 |
| abstract_inverted_index.out | 86 |
| abstract_inverted_index.the | 8, 40, 78, 89, 96, 122, 146, 171, 175, 185, 192, 197, 215, 233, 238 |
| abstract_inverted_index.two | 90 |
| abstract_inverted_index.was | 58, 84, 135, 150, 188, 202 |
| abstract_inverted_index.(IFN | 110 |
| abstract_inverted_index.(IM) | 118 |
| abstract_inverted_index.(MS) | 13 |
| abstract_inverted_index.This | 35 |
| abstract_inverted_index.aims | 37 |
| abstract_inverted_index.does | 235 |
| abstract_inverted_index.have | 27 |
| abstract_inverted_index.less | 163 |
| abstract_inverted_index.more | 151, 256 |
| abstract_inverted_index.oral | 23, 45, 114, 126 |
| abstract_inverted_index.side | 257, 272 |
| abstract_inverted_index.than | 152, 165, 190, 259 |
| abstract_inverted_index.that | 144, 174 |
| abstract_inverted_index.them | 103 |
| abstract_inverted_index.used | 49 |
| abstract_inverted_index.with | 106, 116, 128, 180, 255 |
| abstract_inverted_index.(AEs) | 183 |
| abstract_inverted_index.(MRI) | 230 |
| abstract_inverted_index.2020. | 74 |
| abstract_inverted_index.Also, | 251 |
| abstract_inverted_index.April | 73 |
| abstract_inverted_index.There | 211 |
| abstract_inverted_index.Three | 93 |
| abstract_inverted_index.drugs | 47 |
| abstract_inverted_index.found | 136 |
| abstract_inverted_index.group | 187, 195 |
| abstract_inverted_index.issue | 16 |
| abstract_inverted_index.rates | 223 |
| abstract_inverted_index.study | 36, 134 |
| abstract_inverted_index.their | 81 |
| abstract_inverted_index.there | 263 |
| abstract_inverted_index.third | 123 |
| abstract_inverted_index.used, | 3 |
| abstract_inverted_index.while | 145 |
| abstract_inverted_index.β-1a | 156, 208 |
| abstract_inverted_index.β-1b | 194 |
| abstract_inverted_index.(ARRs) | 224 |
| abstract_inverted_index.(DMDs) | 48 |
| abstract_inverted_index.(DMF). | 140 |
| abstract_inverted_index.events | 182 |
| abstract_inverted_index.higher | 189 |
| abstract_inverted_index.remain | 14 |
| abstract_inverted_index.review | 57 |
| abstract_inverted_index.safety | 41 |
| abstract_inverted_index.widely | 2 |
| abstract_inverted_index.β-1a. | 131, 168, 278 |
| abstract_inverted_index.β-1b, | 120, 261 |
| abstract_inverted_index.(RRMS). | 53 |
| abstract_inverted_index.PubMed, | 64 |
| abstract_inverted_index.Science | 70 |
| abstract_inverted_index.Scopus, | 65 |
| abstract_inverted_index.adverse | 181 |
| abstract_inverted_index.another | 112 |
| abstract_inverted_index.article | 124 |
| abstract_inverted_index.beta-1a | 109 |
| abstract_inverted_index.between | 204, 274 |
| abstract_inverted_index.carried | 85 |
| abstract_inverted_index.effects | 258, 273 |
| abstract_inverted_index.further | 243 |
| abstract_inverted_index.groups. | 209 |
| abstract_inverted_index.imaging | 229 |
| abstract_inverted_index.overall | 198 |
| abstract_inverted_index.quality | 82 |
| abstract_inverted_index.relapse | 222 |
| abstract_inverted_index.related | 61 |
| abstract_inverted_index.results | 142, 172 |
| abstract_inverted_index.safety, | 170 |
| abstract_inverted_index.similar | 203 |
| abstract_inverted_index.studies | 79, 94, 244 |
| abstract_inverted_index.suggest | 268 |
| abstract_inverted_index.support | 237 |
| abstract_inverted_index.β-1a), | 111 |
| abstract_inverted_index.β-1b), | 158 |
| abstract_inverted_index.Although | 1 |
| abstract_inverted_index.Methods: | 54 |
| abstract_inverted_index.Results: | 92 |
| abstract_inverted_index.authors. | 91 |
| abstract_inverted_index.compared | 104, 113, 125 |
| abstract_inverted_index.criteria | 98 |
| abstract_inverted_index.diabetic | 178 |
| abstract_inverted_index.dimethyl | 138 |
| abstract_inverted_index.dramatic | 30 |
| abstract_inverted_index.efficacy | 18, 43, 147, 164 |
| abstract_inverted_index.eligible | 133 |
| abstract_inverted_index.evaluate | 39 |
| abstract_inverted_index.evidence | 213, 234, 266 |
| abstract_inverted_index.fumarate | 139 |
| abstract_inverted_index.magnetic | 227 |
| abstract_inverted_index.multiple | 11 |
| abstract_inverted_index.patients | 179 |
| abstract_inverted_index.reducing | 220 |
| abstract_inverted_index.required | 246 |
| abstract_inverted_index.Cochrane, | 66 |
| abstract_inverted_index.Recently, | 21 |
| abstract_inverted_index.Regarding | 169 |
| abstract_inverted_index.conducted | 59 |
| abstract_inverted_index.databases | 62 |
| abstract_inverted_index.determine | 248 |
| abstract_inverted_index.efficacy. | 250 |
| abstract_inverted_index.findings, | 231 |
| abstract_inverted_index.fulfilled | 95 |
| abstract_inverted_index.improving | 226 |
| abstract_inverted_index.including | 63 |
| abstract_inverted_index.indicated | 143, 173 |
| abstract_inverted_index.medicines | 6 |
| abstract_inverted_index.resonance | 228 |
| abstract_inverted_index.sclerosis | 12 |
| abstract_inverted_index.screening | 76 |
| abstract_inverted_index.treatment | 9 |
| abstract_inverted_index.adherence. | 20 |
| abstract_inverted_index.annualized | 221 |
| abstract_inverted_index.assessment | 83 |
| abstract_inverted_index.associated | 254 |
| abstract_inverted_index.difference | 270 |
| abstract_inverted_index.fingolimod | 115, 127, 149, 186, 218, 252 |
| abstract_inverted_index.first-line | 4 |
| abstract_inverted_index.inclusion. | 100 |
| abstract_inverted_index.injectable | 5 |
| abstract_inverted_index.interferon | 108 |
| abstract_inverted_index.occurrence | 199 |
| abstract_inverted_index.predefined | 97 |
| abstract_inverted_index.proportion | 176 |
| abstract_inverted_index.systematic | 56 |
| abstract_inverted_index.treatment. | 34 |
| abstract_inverted_index.Background: | 0 |
| abstract_inverted_index.Conclusion: | 210 |
| abstract_inverted_index.contributed | 28 |
| abstract_inverted_index.medications | 24 |
| abstract_inverted_index.improvements | 31 |
| abstract_inverted_index.subcutaneous | 107, 166 |
| abstract_inverted_index.effectiveness | 216, 239 |
| abstract_inverted_index.independently | 87 |
| abstract_inverted_index.intramuscular | 117 |
| abstract_inverted_index.teriflonomide | 105 |
| abstract_inverted_index.teriflunomide | 159, 205, 241, 275 |
| abstract_inverted_index.disease-modifying | 46 |
| abstract_inverted_index.relapsing-remitting | 51 |
| cited_by_percentile_year.max | 94 |
| cited_by_percentile_year.min | 90 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6899999976158142 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.44797955 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |